Compound FLZ inhibits lipopolysaccharide-induced inflammatory effects via down-regulation of the TAK-IKK and TAK-JNK/p38MAPK pathways in RAW264.7 macrophages

Acta Pharmacologica Sinica

Volumn 30, Issue 2, 2009, Pages 209-218

  Pang, Hong Yan ^a   Liu, Gang ^a   Liu, Geng Tao ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

COX 2; FLZ; INOS; TAK1

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; DOUBLE STRANDED DNA; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; I KAPPA B; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N 2 (4 HYDROXYPHENYL)ETHYL 2 (2,5 DIMETHOXYPHENYL) 3 (3 METHOXY 4 HYDROXYPHENYL)ACRYLAMIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; BENZENEACETAMIDE DERIVATIVE; FLZ COMPOUND; I KAPPA B KINASE; LIPOPOLYSACCHARIDE; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PHENOL DERIVATIVE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; INFLAMMATION; MACROPHAGE; NEUROPROTECTION; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BENZENEACETAMIDES; CYCLOOXYGENASE 2; DOWN-REGULATION; ENZYME ACTIVATION; I-KAPPA B KINASE; INFLAMMATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MACROPHAGES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MOLECULAR STRUCTURE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOLS;

EID: 65349113645     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2008.29     Document Type: Article

References (41)

1. Xie P, Jiao XZ, Liang XT, Feng WH, Wei HL, Liu GT. Synthesis and antioxiactivity of squamosamide cyclic analogs. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004; 26: 372-8. Chinese.
2. Zhang D, Zhang JJ, Liu GT. The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells. Eur J Pharmacol 2007; 561: 1-6.
3. Zhang D, Zhang JJ, Liu GT. The novel squamosamide derivative (compound FLZ) attenuated 1-methyl-4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells. Neuropharmacology 2007; 52: 423-9.
4. Fang F, Liu GT. Novel squamosamide derivative (compound FLZ) attenuates Abeta(25-35)-induced toxicity in SH-SY5Y cells. Acta Pharmacol Sin 2008; 29: 152-60.
5. Fang F, Liu GT. Protective effects of compound FLZ on betaamyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment. Acta Pharmacol Sin 2006; 27: 651-8.
6. Feng W, Wei H, Liu GT. Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism. Mol Neurobiol 2005; 31: 295-300.
7. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-15.
8. Gilgun-Sherki Y, Melamed E, Offen D. Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Curr Pharm Des 2006; 12: 3509-19.
9. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 2006; 9: 271-6.
10. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003; 4: 103-12.
11. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69.
12. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184: 69-91.
13. Zhang D, Hu X, Wei SJ, Liu J, Gao H, Qian L, et al. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. J Neuroinflammation 2008; 5: 21.
14. Kim YM, Lee BS, Yi KY, Paik SG. Upstream NF-kappaB site is required for the maximal expression of mouse inducible nitric oxide synthase gene in interferon-gamma plus lipopolysaccharideinduced RAW264.7 macrophages. Biochem Biophys Res Commun 1997; 236: 655-60.
15. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases - regulating the immune response. Nat Rev Immunol 2007; 7: 202-12.
16. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005; 6:1087-95.
17. Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 2007; 26: 3159-71.
18. Chen ZJ, Bhoj V, Seth RB. Ubiquitin, TAK1 and IKK: is there a connection? Cell Death Differ 2006; 13: 687-92.
19. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 1997; 69: 581-93.
20. Shin HM, Kim BH, Chung EY, Jung SH, Kim YS, Min KR, et al. Suppressive effect of novel aromatic diamine compound on nuclear factor-kappaB-dependent expression of inducible nitric oxide synthase in macrophages. Eur J Pharmacol 2005; 521: 1-8.
21. Sumanont Y, Murakami Y, Tohda M, Vajragupta O, Matsumoto K, Watanabe H. Evaluation of the nitric oxide radical scavenging activity of manganese complexes of curcumin and its derivative. Biol Pharm Bull 2004; 27: 170-3.
22. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989; 17: 6419.
23. Chen C, Chen YH, Lin WW. Involvement of p38 mitogenactivated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology 1999; 97: 124-9.
24. Jeffrey KL, Camps M, Rommel C, Mackay CR. Targeting dualspecificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 2007; 6: 391-403.
25. Van Broeck B, Van Broeckhoven C, Kumar-Singh S. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener Dis 2007; 4: 349-65.
26. Yuan H, Zheng JC, Liu P, Zhang SF, Xu JY, Bai LM. Pathogenesis of Parkinson's disease: oxidative stress, environmental impact factors and inflammatory processes. Neurosci Bull 2007; 23: 125-30.
27. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-64.
28. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 1995; 57: 707-36.
29. Iadecola C, Zhang F, Xu S, Casey R, Ross ME. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 1995; 15: 378-84.
30. Lau FC, Bielinski DF, Joseph JA. Inhibitory effects of blueberry extract on the production of inflammatory mediators in lipopolysaccharide-activated BV2 microglia. J Neurosci Res 2007; 85: 1010-7.
31. Malinski T. Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 2007; 11: 207-18.
32. Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inflammatory diseases. Mol Med 2000; 6: 347-73.
33. Minghetti L. Role of COX-2 in inflammatory and degenerative brain diseases. Subcell Biochem 2007; 42: 127-41.
34. Kim JH, Kim DH, Baek SH, Lee HJ, Kim MR, Kwon HJ, et al. Rengyolone inhibits inducible nitric oxide synthase expression and nitric oxide production by down-regulation of NF-kappaB and p38 MAP kinase activity in LPS-stimulated RAW264.7 cells. Biochemical Pharmacol 2006; 71: 1198-205.
35. Nomura Y. NF-kappaB activation and IkappaBalpha dynamism involved in iNOS and chemokine induction in astroglial cells. Life Sci 2001; 68: 1695-701.
36. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13: 85-94.
37. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005; 1754: 253-62.
38. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-26.
39. Karin M. Inflammation-activated protein kinases as targets for drug development. Proc Am Thorac Soc 2005; 2: 386-90.
40. Watts C. Location, location, location: identifying the neighborhoods of LPS signaling. Nat Immunol 2008; 9: 343-5.
41. Su B. Linking stress to immunity? Nat Immunol 2005; 6: 541-2.